238 reports of this reaction
1.2% of all ALPELISIB reports
#19 most reported adverse reaction
BREAST CANCER METASTATIC is the #19 most commonly reported adverse reaction for ALPELISIB, manufactured by Novartis Pharmaceuticals Corporation. There are 238 FDA adverse event reports linking ALPELISIB to BREAST CANCER METASTATIC. This represents approximately 1.2% of all 20,016 adverse event reports for this drug.
Patients taking ALPELISIB who experience breast cancer metastatic should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
BREAST CANCER METASTATIC is a less commonly reported adverse event for ALPELISIB, but still significant enough to appear in the safety profile.
In addition to breast cancer metastatic, the following adverse reactions have been reported for ALPELISIB:
The following drugs have also been linked to breast cancer metastatic in FDA adverse event reports:
BREAST CANCER METASTATIC has been reported as an adverse event in 238 FDA reports for ALPELISIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
BREAST CANCER METASTATIC accounts for approximately 1.2% of all adverse event reports for ALPELISIB, making it a notable side effect.
If you experience breast cancer metastatic while taking ALPELISIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.